News | Mobile Devices | June 13, 2018

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

Use of medication management mobile app increased prescription refill rates by almost 10 percent

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients increase their prescription refills by almost 10 percent after they start using the company's mobile app.

In order to determine the increase in prescription claims, the study matched Medisafe users to their refill data using a HIPAA-compliant, non-identification process. The investigators calculated a medication possession ratio ("MPR") for each of the over 4,000 patients taking an antihypertensive medication pre-app (before the patient started using Medisafe) and on-app (once the patient started using Medisafe) and grouped them into corresponding MPR deciles (0 - 0.1 being the least adherent, 0.9 - 1.0 being the most adherent). MPR is a standard metric used by the healthcare industry to track medication adherence, in which an MPR of 1.0 corresponds to a 100 percent refill rate.  

Key findings include:

  • Of patients not in the top MPR decile pre-app, 82 percent (1,371 of 1,667) increased by at least one decile on-app;
  • Of patients with a pre-app MPR < 0.8, 78 percent (920 of 1,179) increased by at least 2 deciles;
  • Of patients with a pre-app MPR < 0.5, 74 percent of patients (320 of 431) increased by at least 5 deciles; and
  • The proportion of patients with MPR ≥ 0.80 increased from 70.8 percent pre-app to 86.25 percent on-app, a 21.8 percent relative increase.

 

Summary Table

Adherence (MPR) Pre-app On-app p-value % change
Mean 0.84 0.92 <.0001 9.52%
Standard deviation 0.23 0.13    
Adherent [MPR ≥ 0.80] 2858 (71%) 3482 (86%) <.0001 21.13%

N= 4,037

 

The hypertension results follow data released from the same landmark study in early March on the accuracy of Medisafe's patient reported adherence data. In the coming months, Medisafe will continue to release results, including data regarding the platform's impact on adherence and persistence across other therapeutic areas.

For more information: www.medisafe.com


Related Content

News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
Subscribe Now